Dr. Narendra Chirmule
Dr Narendra Chirmule is the CEO of Symphony Tech Biologics and an Adjunct Professor at the University of Pennsylvania. He has been the Senior Vice President of Biocon, the Director of Merck, and has close associations with academia and industry.
In our meeting with him, he made us understand the importance of our work, and we came into newfound motivation. He noted that our methodologies could substantially impact researchers working on process development and strain engineering of new recombinant proteins or biotechnology-based startups. He recommended that we have proof of concept at the earliest so that we would be better informed to have nuanced discussions concerning the logistics and the cost of operations, including the use of specific 5’ UTRs with the industry. He said that changing the already existing processes would not be easy as heavy expenditure may be involved at clinical trial stages. Besides this, he also suggested that we should consider how we would protect our intellectual property rights and procure funding for further activities. We have discussed this in the Proposed Implementation segment.
